MarginsXMarginsX
Home › Markets › Health Care › INVA

Innoviva Inc. (INVA)

INVA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$18.49
-2.84% on the day
Market cap
$1.3B
Small cap
Revenue · 2025
$411.3M
+14.7% on 2024
Net income · 2025
$271.2M
65.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1080014/000119312526071776/0001193125-26-071776-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerINVA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2004
SEC CIK0001080014
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$411.3M
Net income$271.2M
Operating income$163.7M
Net margin65.9%
Operating margin39.8%
Revenue growth+14.7%
Cash$550.9M
Total assets$1.6B
P/E (computed)4.8×
P/S (computed)3.2×

Warning signs

Cash runway
Cash-flow positive
$581.4M cash at September 30, 2026
Share count, 1 year
-4.9%
2025-10-31 to 2026-10-31 · +10.9% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$581.4M cash; operating cash flow $45.9M a quarter.Report 2026-09-30
Shares outstanding71,081,477 (2026-10-31); 74,769,062 a year earlier; 64,086,675 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Jose, California, United StatesPCAOB Form AP 2026-03-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$106.1M-$73.9M$41.7M$581.4M$258.8M$438.3M10-Q 2026-11-04
Q2 2026
2026-06-30
$119.6M-$83.4M$52.0M$570.4M$258.5M$440.0M10-Q 2026-08-05
Q1 2026
2026-03-31
$98.0M$186.6M$35.3M$603.1M$258.1M$420.7M10-Q 2026-05-06
Q4 2025
2025-12-31
$114.6M$164.2M$54.5M$550.9M$257.7M$411.3M10-K 2026-02-25
Q3 2025
2025-09-30
$107.8M$89.9M$49.7M$476.5M$257.4M$388.5M10-Q 2026-11-04
Q2 2025
2025-06-30
$100.3M$63.7M$44.1M$397.5M$448.9M$370.2M10-Q 2026-08-05
Q1 2025
2025-03-31
$88.6M-$46.6M$48.6M$319.1M$448.9M$369.8M10-Q 2026-05-06
Q4 2024
2024-12-31
$91.8M$20.3M$59.2M$305.0M$448.3M$358.7M10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52013-01-18
Latest annual report10-K/A2026-03-27
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEF 14A2026-03-24

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.4%
1 month-8.2%
3 months-8.3%
Year to date-4.8%
1 year-14.3%
From 52-week high-21.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OCULOcular Therapeutix Inc.$6.01-3.22%$1.3B
AVLNAvalyn Pharma Inc.$29.76-1.72%$1.3B
GPCRStructure Therapeutics Inc.$18.57-7.15%$1.3B
MLYSMineralys Therapeutics Inc.$14.53-5.22%$1.3B
GHRSGH Research PLC$18.75-1.83%$1.3B
GENBGenerate Biomedicines Inc.$10.49-13.09%$1.4B
NUVBNuvation Bio Inc.$3.84-3.76%$1.4B
MNKDMannKind Corporation$3.96-4.24%$1.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier